Product Deployment, Recognitions, Stock Price Updates, Financial Results, and Positive Court Rulings - Analyst Notes on Microchip, Teradyne, Ambarella, Spansion, and ReneSola

Mar 19, 2014 8:00 AM

NEW YORK, March 19, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Microchip Technology Inc. (NASDAQ: MCHP), Teradyne, Inc. (NYSE: TER), Ambarella Inc (NASDAQ: AMBA), Spansion Inc. (NYSE: CODE), and ReneSola Ltd. (NYSE: SOL). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

--

Microchip Technology Inc. Analyst Notes

On March 4, 2014, Microchip Technology Inc. (Microchip) reported that it has been recognized by 11 global electronic industry publications for the product innovation and technology leadership of its patented GestIC® technology. Microchip stated that the GestIC® technology allows the next dimension in intuitive, gesture-based, non-contact user interfaces for a broad range of end products. The Company informed that MGC3130, the world's first electrical-field (E-field)-based 3D gesture controller that utilizes GestIC technology to provide low-power, precise, fast and robust hand position tracking with free-space gesture recognition, has won five awards in the Americas, three in Asia, and three in Europe. "The sheer number of awards that we've won is a testament to our GestIC technology's ability to enable new and innovative user-interface capabilities in a broad range of products," said Fanie Duvenhage, Director of Microchip's Human Machine Interface Division. "Our MGC3130 controller represents a gigantic leap forward in 3D, touchless gesture-interface technology, in terms of cost, performance and power consumption." The full analyst notes on Microchip Technology Inc. are available to download free of charge at:

http://www.AnalystsReview.com/03192014/MCHP/report.pdf

--

Teradyne, Inc. Analyst Notes

On March 14, 2014, shares of Teradyne, Inc. (Teradyne) gained 0.16% to end the day's trading at \$19.28. Shares of Teradyne declined 1.68% over the past three trading sessions, as compared to the S&P 500 Index which dropped 1.42% during the same period. The full analyst notes on Teradyne, Inc. are available to download free of charge at:

http://www.AnalystsReview.com/03192014/TER/report.pdf

--

Ambarella Inc. Analyst Notes

On March 6, 2014, Ambarella Inc. (Ambarella) released its Q4 FY 2014 and FY 2014 financial results (period ended January 31, 2014). Total revenues for Q4 FY 2014 increased 26.8% YoY to \$40.0 million, and total revenues in FY 2014 increased 30.2% YoY to \$157.6 million. Ambarella's Q4 FY 2014 net income was \$5.5 million or \$0.18 per diluted share, versus \$3.6 million or \$0.13 per diluted share in Q4 FY 2013. Net income stood at \$25.7 million or \$0.85 per diluted share in FY 2014, versus \$18.2 million or \$0.60 per diluted share in FY 2013. Commenting on the results, Fermi Wang, President and CEO of Fermi Wang, stated, "We are very pleased with our fourth quarter and fiscal year 2014 financial results. During the fourth quarter we had revenue of \$40M, up 26.8% from the same period last year. Our revenue for the whole fiscal year was up 30.2% from last year, while revenue from IP-security cameras more than doubled. In Q4 we introduced innovative surround-view solutions for the automotive market and collaborated with Google to explore new opportunities in wearable cameras. We look forward to driving continued innovation in the year ahead." The full analyst notes on Ambarella Inc. are available to download free of charge at:

http://www.AnalystsReview.com/03192014/AMBA/report.pdf

--

Spansion Inc. Analyst Notes

On March 11, 2014, Spansion Inc. (Spansion) reported that the United States District Court of Virginia has ruled two decisions in the Company's favor. The Company informed that the first court order dismissed the case filed by Macronix against Spansion, stating that Macronix's allegations have failed to state a valid case for patent infringement. The Company added that in the second order, the court held that, if Macronix files another complaint, the case will be transferred to the U.S. District Court of the Northern District of California, which could take more than a year for a decision. Ali Poukeramati, Senior Vice President of Spansion, said, "We are pleased with the Court's decision, which confirms that Macronix's complaint failed to demonstrate infringement, and should provide relief to our customers. Since this is the second time that the court in Virginia has dismissed Macronix's complaint against Spansion for this exact same reason, it is obvious that Macronix filed this case only to deflect attention from the suit filed by Spansion against Macronix with the International Trade Commission (ITC)." The full analyst notes on Spansion Inc. are available to download free of charge at:

http://www.AnalystsReview.com/03192014/CODE/report.pdf

--

ReneSola Ltd. Analyst Notes

On March 13, 2014, ReneSola Ltd. (ReneSola) announced that it will deliver 66 Replus string inverters and 100 Micro Replus micro inverters to Enlightened Solar. According to ReneSola, the inverters, along with 2,000 ReneSola 240W and 260W Virtus II modules will be installed by Enlightened Solar on a series of new housing projects in the United Kingdom. Commenting on the update, Geoff Fox, Managing Director of Enlightened Solar said, "We chose ReneSola products because of the long expertise that the company has in supplying top quality equipment. The ease of procurement and full after sales service from the UK office made ReneSola an easy choice." The full analyst notes on ReneSola Ltd. are available to download free of charge at:

http://www.AnalystsReview.com/03192014/SOL/report.pdf

--

About Analysts Review

We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

					_	
					=	

EDITOR NOTES:

- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
- **For any urgent concerns or inquiries**, please contact us at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document.

Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review